This study is for adults with active ulcerative colitis (UC), which causes swelling and bleeding in the colon's lining. The study aims to test how safe and effective a new drug, lutikizumab, is compared to a current treatment, adalimumab. Participants will receive the medicine through an IV (intravenous, which means into a vein) or SC (subcutaneous, which means under the skin). The study has two parts: a 12-week Induction Period and a 52-week Maintenance Period. During the first 12 weeks, participants will get lutikizumab or adalimumab. After 12 weeks, those responding well to lutikizumab will continue with it, and those on adalimumab will stay on it. If the medicine isn't working, participants will switch to a different form of lutikizumab. Around 200 people will join this study, which will take place at about 280 locations worldwide. Participants might face more treatment steps than usual and will go for regular check-ups, blood tests, and fill out surveys.

• The study lasts up to 52 weeks, with an optional additional 52-week extension.
• Participants will visit clinics or hospitals regularly for check-ups.
• There might be a higher treatment burden compared to usual care.